SEC Form 4 · accession 0001415889-17-000679
Vistagen Therapeutics, Inc. · VTGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shawn Singh
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Apr 26, 2017
Accepted (ET)
Apr 28, 2017 · 3:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411685
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.96 | Apr 26, 2017 | A | 175,000 | A | — | Apr 26, 2027 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1One third (1/3rd) of the total shares shall vest one (1) year following the date of grant and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested three (3) years from the date of grant.